跳转至内容
Merck
  • Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma.

Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma.

iScience (2022-11-09)
Joana B Neves, Kirsty Roberts, Janani Sivakumaran Nguyen, Soha El Sheikh, My-Anh Tran-Dang, Catherine Horsfield, Faiz Mumtaz, Peter Campbell, Hans Stauss, Maxine G B Tran, Thomas Mitchell
摘要

Succinate dehydrogenase (SDH)-deficient renal cell carcinoma represents a rare subtype of hereditary kidney cancer. Clinical diagnosis can be challenging and there is little evidence to guide systemic therapeutic options. We performed genomic profiling of a cohort of tumors through the analysis of whole genomes, transcriptomes, as well as flow cytometry and immunohistochemistry in order to gain a deeper understanding of their molecular biology. We find neutral evolution after early tumor activation with a lack of secondary driver events. We show that these tumors have epithelial derivation, possibly from the macula densa, a specialized paracrine cell of the renal juxtaglomerular apparatus. They subsequently develop into immune excluded tumors. We provide transcriptomic and protein expression evidence of a highly specific tumor marker, PAPPA2. These translational findings have implications for the diagnosis and treatment for this rare tumor subtype.

材料
货号
品牌
产品描述

Roche
重组DNase I,无RNase, from bovine pancreas, expressed in Pichia pastoris
Sigma-Aldrich
IV型胶原酶,Cls IV
Sigma-Aldrich
Anti-PAPPA2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution